INFORMATION INTENDED FOR GLOBAL HEALTHCARE PROFESSIONALS

Pipeline

GW’s extensive research into the pharmacology of cannabinoids continues to yield highly promising data and new intellectual property across a range of therapeutic areas. GW continues to invest in research to accelerate further growth and value creation through the development of medicines that address serious unmet medical needs.

Products
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Pharmaceutical Development Pipeline
Products
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Epidiolex
PRODUCTS
Epidiolex Dravet Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
Epidiolex Lennox-Gastaut Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
Epidiolex Tuberous Sclerosis Complex
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
Epidiolex Rett Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Sativex® (US)
PRODUCTS
Sativex MS Spasticity
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
Sativex NEUROPATHIC PAIN / OTHER NEUROLOGICAL SYMPTOMS
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
CBDV (GWP42006)
PRODUCTS
GWP42006 (CBDV) Epilepsy
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
GWP42006 (CBDV) Autism Spectrum Disorders
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Other
PRODUCTS
GWP42003 (IV) Neonatal Hypoxic-Ischemic Encephalopathy
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
GWP42002 / GWP42003 GLIOBLASTOMA
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
PRODUCTS
GWP42003 Schizophrenia
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved